We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Identified Genes Associated with Unhealthy Liver Function

By LabMedica International staff writers
Posted on 16 Oct 2013
Genes associated with unhealthy liver function have been identified in overweight patients with diabetes in a groundbreaking study.

Nonalcoholic fatty liver disease (NAFLD) is the buildup of extra fat in liver cells, not caused by alcohol and it is one of the most common causes of chronic liver disease. More...
Steatohepatitis (NASH) is liver inflammation and damage caused by a buildup of fat in the liver, not caused by alcohol.

Scientists at the Translational Genomics Research Institute (TGen; Phoenix, AZ, USA) carried out a genome-wide analysis to identify loci associated with total bilirubin levels, steatosis, and mild fibrosis in nonalcoholic fatty liver disease. They examined how genomic factors affect the development of nonalcoholic fatty liver disease. There were nearly 2,300 patients included in the study and all with extreme obesity enrolled in a bariatric surgery program.

The study identified evidence for association with markers in the neurocan gene (NCAN) on chromosome 19p12, and rs2501843 on chromosome 1. Johanna DiStefano, PhD, the Director of Translational Genomics Research Institute’s Diabetes, Cardiovascular and Metabolic Diseases Division, and the study’s principal investigator, said, “These genetic factors could help us identify patients who are most at risk of developing nonalcoholic forms of fatty-liver disease (NAFLD), and which patients may be more likely to progress to severe forms of NAFLD, such as steatohepatitis (NASH).”

Glenn S. Gerhard, MD, a co-investigator of the study and a faculty member of the Geisinger Obesity Institute (Danville, PA, USA) and the Administrative Director for the Institute for Personalized Medicine at Penn State Hershey Medical Center (Hershey, PA, USA) added, “Our results showed evidence for new genetic loci that may play a role in the biological mechanisms of NAFLD and NASH. We discovered genes that may help identify those patients most at risk for the types of liver disease so severe that they could require transplants." The study was presented at the 64th annual meeting of the American Association for the Study of Liver Diseases held November 1-5, 2013, in Washington DC (USA).

Related Links:
Translational Genomics Research Institute
Geisinger Obesity Institute
Penn State Hershey Medical Center


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Hematology Consumables
Bioblood Devices
Automatic CLIA Analyzer
Shine i6000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers from the Department of Chemistry at Aarhus University have developed and tested a new technology that can identify and measure the concentration of pharmaceuticals in under 10 minutes. Today, this process takes up to an hour. That is critical waiting time for patients suffering from a stroke. (Image Credit: Aarhus University)

Point-of-Care Blood Test Could Speed Treatment Decisions in Acute Stroke

Minutes can shape treatment decisions in emergency stroke care, particularly when physicians need to know whether a patient is taking anticoagulants before administering clot-dissolving therapy.... Read more

Microbiology

view channel
Image: The clearance also broadens QIAstat-Dx\'s infectious disease testing menu in the U.S., which already includes panels for respiratory and gastrointestinal infections, as well as meningitis and encephalitis (Photo courtesy of Qiagen)

One-Hour Molecular Panel Expands Bloodstream Infection Testing for Gram-Negative Pathogens

Bloodstream infections can progress rapidly and lead to sepsis, organ failure, and death. In the United States, about 1.7 million adults develop sepsis each year, and at least 350,000 die during hospitalization... Read more

Industry

view channel
Image

Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection

Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.